We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
+6.47%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$3.15B
AUM Growth
-$465M
(-13%)
Cap. Flow
-$168M
Cap. Flow
% of AUM
-5.34%
Top 10 Holdings %
Top 10 Hldgs %
68.44%
Holding
41
New
4
Increased
7
Reduced
9
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ascendis Pharma A/S
ASND
|
+$94.5M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$86.4M |
| 3 |
Zimmer Biomet
ZBH
|
+$62.8M |
| 4 |
Medpace
MEDP
|
+$47.5M |
| 5 |
CON
Concentra Group Holdings
CON
|
+$45.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Universal Health Services
UHS
|
+$178M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
+$90.6M |
| 3 |
WBA
Walgreens Boots Alliance
WBA
|
+$84.7M |
| 4 |
Humana
HUM
|
+$71.2M |
| 5 |
Myriad Genetics
MYGN
|
+$42M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 80.29% |
| 2 | Miscellaneous | 18.96% |
| 3 | Consumer Staples | 0.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Herbalife
HLF
$1.25B
| $21.6M | 0.69% |
3,000,000
| – | – |
|
|
BCYC
27
Bicycle Therapeutics
BCYC
$257M
| $20.7M | 0.66% |
915,000
| – | – |
|
28
Inogen
INGN
$138M
| $19.4M | 0.62% |
2,000,000
| – | – |
|
29
OraSure Technologies
OSUR
$239M
| $18.1M | 0.58% |
4,250,000
| – | – |
|
30
Theravance Biopharma
TBPH
$885M
| $8.06M | 0.26% |
1,000,000
| – | – |
|
31
Alkermes
ALKS
$7.72B
| $5.6M | 0.18% |
+200,000
| New | +$5.33M |
|
32
SkinHealth Systems
SKIN
$87.8M
| $2.16M | 0.07% |
1,500,000
-2,000,000
| -57% | -$3.28M |
|
33
Genmab
GMAB
$21B
| $1.22M | 0.04% |
50,000
| – | – |
|
34
AnaptysBio
ANAB
$1.62B
| – | – |
-500,000
| Closed | -$12.5M |
|
35
argenx
ARGX
$61.3B
| – | – |
-72,000
| Closed | -$31M |
|
|
36
BioMarin Pharmaceuticals
BMRN
$12.5B
| – | – |
-1,100,000
| Closed | -$90.6M |
|
|
CVAC
37
DELISTED
CureVac
CVAC
| – | – |
-550,000
| Closed | -$1.87M |
|
38
CALL
Pfizer
PFE
$157B
| – | – |
-2,500,000
| Closed | -$70M |
|
39
Perrigo
PRGO
$1.88B
| – | – |
-1,520,000
| Closed | -$39M |
|
40
Replimune Group
REPL
$1.23B
| – | – |
-1,350,000
| Closed | -$12.2M |
|
|
WBA
41
DELISTED
Walgreens Boots Alliance
WBA
| – | – |
-7,000,000
| Closed | -$84.7M |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q3 2024 Portfolio in Review
As of Q3 2024, Camber Capital Management held 41 positions worth $3.15B, down 13% from $3.61B the previous quarter. Its ten largest holdings account for 68% of the portfolio.
Camber Capital Management withdrew a net $168M in Q3 2024, closing 8 positions and reducing 9 holdings. Its most notable exit was BioMarin Pharmaceuticals, an estimated $90.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 70% a quarter earlier, followed by Miscellaneous and Consumer Staples.
Against the trend, Camber Capital Management opened a new position in Ascendis Pharma A/S worth $105M.
- Camber Capital Management's largest Q3 2024 buy was Ascendis Pharma A/S: 700,000 shares worth $105M.
- Camber Capital Management added most to Sarepta Therapeutics in Q3 2024, an estimated $86.4M increase.
- Camber Capital Management's biggest Q3 2024 reduction was Universal Health Services, cutting an estimated $178M.
- Camber Capital Management fully exited BioMarin Pharmaceuticals in Q3 2024, selling an estimated $90.6M.
- Camber Capital Management's ten largest holdings make up 68% of its $3.15B portfolio in Q3 2024.
- Camber Capital Management opened 4 new positions and closed 8 in Q3 2024.
- Camber Capital Management's portfolio value fell 13% quarter-over-quarter to $3.15B.
Based on Camber Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.